Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026
Effectiveness of seasonal influenza vaccine 2025/2026 among persons 65 years and older: a cohort study in Stockholm County, Sweden.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amin Ridwanul, Hergens Maria Pia, Nauclér Pontus, Widgren Katarina
Аннотация
OBJECTIVES: To estimate vaccine effectiveness (VE) against any influenza, outpatient visits and hospitalisations for influenza, and 30-day all-cause mortality among community-dwelling adults aged ≥65 years during a period dominated by influenza A(H3N2) subclade K in the 2025/2026 season in Stockholm County, Sweden.
METHODS: A population-based cohort study was conducted among all residents aged ≥65 years in Stockholm County (n = 415 779) from 3 November 2025 to 22 February 2026. Individuals residing in nursing homes or with recent influenza diagnoses were excluded. Influenza vaccinations (from Vaccinera), healthcare encounters and date of death (from regional healthcare data warehouse - Swedish acronym VAL), were linked using pseudonymised identifiers. VE was estimated using Cox proportional hazards models, adjusted for age, sex, socioeconomic status, healthcare seeking behaviour and specific comorbidity. VE was calculated as (1 - hazard ratio) × 100% with 95% CIs, and analyses were stratified by age groups 65-74 and ≥75 years.
RESULTS: Approximately two-thirds of the cohort were vaccinated, and 54% were aged ≥75 years. Vaccinated individuals tended to be older and have higher socioeconomic status, specific comorbidities and prior vaccination history. VE (95% CI) during the study period was 38% (32-44) against any influenza, 27% (8-42) against outpatient visits, 39% (32-45) against hospitalisations and 56% (34-70) against 30-day all-cause mortality after an influenza-related hospitalisation. Age-stratified analyses yielded similar estimates. No vaccinated individuals aged 65-74 years experienced 30-day mortality.
CONCLUSIONS: During a season with influenza A(H3N2) subclade K dominance, seasonal influenza vaccination provided low to moderate protection against outpatient visits and hospitalisations, and moderate protection against 30-day all-cause mortality among older adults. These findings reinforce the value of seasonal influenza vaccination for older populations and highlight the need for continued viral surveillance and VE monitoring.
METHODS: A population-based cohort study was conducted among all residents aged ≥65 years in Stockholm County (n = 415 779) from 3 November 2025 to 22 February 2026. Individuals residing in nursing homes or with recent influenza diagnoses were excluded. Influenza vaccinations (from Vaccinera), healthcare encounters and date of death (from regional healthcare data warehouse - Swedish acronym VAL), were linked using pseudonymised identifiers. VE was estimated using Cox proportional hazards models, adjusted for age, sex, socioeconomic status, healthcare seeking behaviour and specific comorbidity. VE was calculated as (1 - hazard ratio) × 100% with 95% CIs, and analyses were stratified by age groups 65-74 and ≥75 years.
RESULTS: Approximately two-thirds of the cohort were vaccinated, and 54% were aged ≥75 years. Vaccinated individuals tended to be older and have higher socioeconomic status, specific comorbidities and prior vaccination history. VE (95% CI) during the study period was 38% (32-44) against any influenza, 27% (8-42) against outpatient visits, 39% (32-45) against hospitalisations and 56% (34-70) against 30-day all-cause mortality after an influenza-related hospitalisation. Age-stratified analyses yielded similar estimates. No vaccinated individuals aged 65-74 years experienced 30-day mortality.
CONCLUSIONS: During a season with influenza A(H3N2) subclade K dominance, seasonal influenza vaccination provided low to moderate protection against outpatient visits and hospitalisations, and moderate protection against 30-day all-cause mortality among older adults. These findings reinforce the value of seasonal influenza vaccination for older populations and highlight the need for continued viral surveillance and VE monitoring.